/
Our Business We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema ( HAE ) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discover…
$9.29
+$0.18 (+1.98%)
EOD Jul 17, 2026
Margins and capital returns are both well above average: 38.98% operating margin, ROIC at 198.90%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 94.1% YoY with margins expanding 39.5pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$886M
▲ +94.1% YoY
Net Income (TTM)
-$458M
▲ +396.9% YoY
Op. Margin
-43.11%
▲ +39.5pp YoY
ROIC
-136.51%
▲ +199.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$310M
▲ +749.0% YoY
Op. Cash Flow (TTM)
$313M
▲ +767.8% YoY
Net Debt
$172M
Cash & Equiv.
$238M
5Y CAGR: +117.9%
Continue Research
BioCryst Pharmaceuticals (BCRX) trades below a two-stage DCF intrinsic value of about $21.49 per share, so at $9.29 the stock looks undervalued (131.3% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, BioCryst Pharmaceuticals scores 60/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $21.49 per share for BCRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $16.12. At today's $9.29, that puts the stock about 131.3% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
BioCryst Pharmaceuticals scores 60 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a -43.1% operating margin and a -136.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. BCRX currently trades below its estimated intrinsic value and scores 60/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.